EVALUATION OF THE EPIDEMIOLOGICAL IMPACT OF VACCINATION AGAINST SARS-COV-2 IN THE STATE OF GOIÁS IN 2021

Visualizações: 131

Authors

DOI:

https://doi.org/10.56579/rei.v7i5.1791

Keywords:

COVID-19, SARS-CoV-2, Goiás, Vaccination

Abstract

ABSTRACT:

Introduction: Vaccines against the COVID-19 pandemic were an efficient strategy in reducing the number of cases of infection by the SARS-COV2 virus and its variants. Objective: To evaluate the impact of the vaccination campaign against COVID-19, in the state of Goiás. Methodology: Cross-sectional, retrospective epidemiological study in which the influence of the total number of doses of vaccines against COVID-19 applied on the number of confirmed cases, the number of confirmed cases that required ICU admission, the average length of stay in the ICU and the clinical outcome of these cases admitted to the ICU. Results: During the period analyzed, 10,813,451 doses of vaccine were administered and 634,336 new cases were confirmed. In epidemiological week 9, the highest value of the analyzed period was recorded, while after epidemiological week 28, there was a slowdown in the number of new confirmed cases. In 2021, an increase in the number of hospitalizations was observed in the first half of the year. From epidemiological week 29 onwards, there was a decrease in the number of new ICU admissions. The average length of stay in the ICU was 10.9 days and on average 47.9% of confirmed cases of COVID-19 admitted to the ICU were discharged from the hospital. Conclusion: Advances in vaccination in the state of Goiás generated a progressive reduction in the number of confirmed cases and confirmed cases that required ICU admission. For the length of stay in the ICU of confirmed cases of COVID-19 and respective clinical outcome, this relationship was not observed.

Keywords: COVID-19; Vaccination; SARS-COV-2; Goiás.

Downloads

Download data is not yet available.

Author Biographies

Guilherme Silveira Rocha, Federal University of Jataí

Undergraduate Medical Student at the Federal University of Jataí, Brazil, Goiás, Jataí.

Tamara Rodrigues Lima Zanuzzi, Federal University of Goiás

Bachelor’s degree in Psychology from the Federal University of Goiás (2012). Professional Master’s in Public Health from the Institute of Tropical Pathology and Public Health (IPTSP) at the Federal University of Goiás (2023). Postgraduate studies in Epidemiology and Health, Traffic Psychology, Psychological Assessment, and Psychonephrology.

Edlaine Faria de Moura Villela, University of São Paulo

Epidemiologist with experience in public health surveillance; public health policy and management; and health promotion, education, and communication. Postdoctoral studies in: Evaluation of Public Health Policies at the Instituto de Salud Carlos III/Madrid; Medical Education at the School of Medicine of Ribeirão Preto, University of São Paulo (USP); Global Health with application of Mixed Epidemiological Methods at the Institute of Global Health, University of Antwerp/Belgium; Open Science and Health Policy at Universidad Carlos III de Madrid. Ph.D. in Epidemiology and Master’s in Public Health from the School of Public Health, USP.

Fábio Morato Oliveira, Federal University of Jataí

Holds a Bachelor’s degree in Biological Sciences from the University of Brasília (UnB) (1999), a Master’s degree from the Graduate Program in Molecular Pathology (UnB), and a Ph.D. from the Graduate Program in Genetics, School of Medicine of Ribeirão Preto, USP, in 2007. Postdoctoral research at the National Institute of Science and Technology in Stem Cells and Cell Therapy / Department of Internal Medicine (FMRP/USP).

References

BASTOS, L. S. et al. COVID-19 hospital admissions: Brazil’s first and second waves compared. The Lancet Respiratory Medicine, [s. l.], v. 9, n. 8, p. e82–e83, 2021.Avaliable from: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00287-3/fulltext. Acess on 10 mai. 2024. DOI: https://doi.org/10.1016/S2213-2600(21)00287-3

BEERAKA, N. M. et al. Development of antibody resistance in emerging mutant strains of SARS CoV‐2: Impediment for COVID‐19 vaccines. Reviews in Medical Virology, [s. l.], 2022. Avaliable from: https://pubmed.ncbi.nlm.nih.gov/35416390/. Acess on 12 mai. 2024. DOI: https://doi.org/10.1002/rmv.2346

BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Guia de Vigilância Epidemiológica Emergência de Saúde Pública de Importância Nacional pela Doença pelo Coronavírus 2019 - Vigilância Integrada de Síndromes Respiratórias Agudas Doença pelo Coronavírus 2019, Influenza e outros vírus respiratórios. 2020. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/guia_vigilancia_epidemiologica_emergencia_saude_publica_importancia_nacional_doenca_coranvirus.pdf. Acesso em: 10 maio 2024.

BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Plano Nacional de Operacionalização da Vacinação Contra a COVID-19. [S. l.], n. 12, 2022a. Disponível em: https://www.gov.br/saude/pt-br/assuntos/covid-19/publicacoes-tecnicas/guias-e-planos/plano-nacional-de-operacionalizacao-da-vacinacao-contra-covid-19.pdf. Acesso em: 10 maio 2024.

BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. BOLETIM EPIDEMIOLÓGICO ESPECIAL - Doença pelo Coronavírus COVID-19 Semana Epidemiológica 52. 2022b. Disponível em: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/covid-19/2022. Acesso em 12 mai. 2024.

FERGUSON, N. et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. [S. l.], 2020. Avaliable from: https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf. Acesso on: 14 mai. 2024.

GOIÁS. Secretaria de Estado da Saúde; Superintendência de Vigilância em Saúde. BOLETIM EPIDEMIOLÓGICO COVID-19 N°. 78 – 07/01/2021. 2021. Disponível em: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/covid-19/2021. Acesso em: 10 maio 2024.

JERGOVIĆ, M. et al. Immune response to COVID-19 in older adults. The Journal of Heart and Lung Transplantation, [s. l.], v. 40, n. 10, p. 1082–1089, 2021. Avaliable from: https://www.jhltonline.org/article/S1053-2498(21)02303-2/fulltext. Acess on: 03 jun. 2024. DOI: https://doi.org/10.1016/j.healun.2021.04.017

KARIM, S. S. A.; KARIM, Q. A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. The Lancet, [s. l.], v. 398, n. 10317, 2021. Avaliable from: https://pubmed.ncbi.nlm.nih.gov/34871545/. Acess on 10 mai. 2024. DOI: https://doi.org/10.1016/S0140-6736(21)02758-6

KYRIAKIDIS, N. C. et al. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines, [s. l.], v. 6, n. 1, 2021. Avaliable from: https://pubmed.ncbi.nlm.nih.gov/34871545/. Acess on: 13 mai. 2024. DOI: https://doi.org/10.1038/s41541-021-00292-w

LI, B. et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. Nature Communications, [s. l.], v. 13, n. 1, p. 460, 2022. Available from: https://pubmed.ncbi.nlm.nih.gov/35075154/. Acess on: 03 jun. 2024.

LIU, H. et al. Herd immunity induced by COVID-19 vaccination programs and suppression of epidemics caused by the SARS-CoV-2 Delta variant in China. MedRxiv, [s. l.], 2021. Avaliable from: https://pubmed.ncbi.nlm.nih.gov/34341803/. Acess on: 10 mai. 2024. DOI: https://doi.org/10.1101/2021.07.23.21261013

MALIK, J. A. et al. The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges. Journal of Infection and Public Health, [s. l.], v. 15, n. 2, p. 228–240, 2022. Avaliable from: https://pubmed.ncbi.nlm.nih.gov/35042059/. Acess on: 03 jun. 2024. DOI: https://doi.org/10.1016/j.jiph.2021.12.014

MARTINS-FILHO, P. R. et al. Dynamics of hospitalizations and in-hospital deaths from COVID-19 in Northeast Brazil: a retrospective analysis based on the circulation of SARS-CoV-2 variants and vaccination coverage. Epidemiology and Health, [s. l.], v. 44, p. e2022036, 2022. Avaliable from: https://pubmed.ncbi.nlm.nih.gov/35413166/. Acess on 10 mai. 2024. DOI: https://doi.org/10.4178/epih.e2022036

MASCARELLO, K. C. et al. Hospitalização e morte por COVID-19 e sua relação com determinantes sociais da saúde e morbidades no Espírito Santo: um estudo transversal. Epidemiologia e Serviços de Saúde, [s. l.], v. 30, n. 3, 2021. Disponível em: https://www.scielo.br/j/ress/a/vwnZ8DMcbGxJghC5CbTnZ8b/. Acesso em 11 mai. 2024. DOI: https://doi.org/10.1590/s1679-49742021000300004

ORELLANA, J. D. Y. et al. Cambios en el patrón de internamientos y óbitos por COVID-19 tras una elevada vacunación de ancianos en Manaos, Amazonas, Brasil. Cadernos de Saúde Pública, [s. l.], v. 38, n. 5, 2022. Avaliable from: https://www.scielo.br/j/csp/a/gBLRDMGKcV3nTtYWBfL4R4b/abstract/?lang=pt. Acess on: 03 jun. 2024. DOI: https://doi.org/10.1590/0102-311xpt192321

POLACK, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, [s. l.], v. 383, n. 27, 2020. Avaliable from: https://pubmed.ncbi.nlm.nih.gov/33301246/. Acess on: 10 mai. 2024.

SARDENBERG, R. A. S. et al. Factors related to survival in Intensive Care Unit patients with Covid-19: a study from a single center in Brazil. SciELO Preprints, [s. l.], 2022. Avaliable from: https://preprints.scielo.org/index.php/scielo/preprint/view/4453. Acess on: 11 mai. 2024. DOI: https://doi.org/10.1590/SciELOPreprints.4453

WANG, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, [s. l.], v. 592, p. 1–7, 2021. Avaliable from: https://pubmed.ncbi.nlm.nih.gov/33567448/. Acess on: 10 mai. 2024.

WHO. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. [s. l.], 2020. Avaliable from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Acess on: 09 mai. 2024.

WHO. Word Health Organization. COVID-19 Weekly Epidemiological Update 28 December 2021. 2021a. Avaliable from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20211228_weekly_epi_update_72.pdf?sfvrsn=7a3567d4_3. Acess on 09 mai. 2024.

WHO. Word Health Organization. 2nd Golbal consultation on assessing the impact of SARS-CoV-2 Variants of Concern on Public Health Interventions – 10 June 2021. 2021b. Avaliable from: https://www.who.int/publications/m/item/2nd-global-consultation-on-assessing-the-impact-of-sars-cov-2-variants-of-concern-on-public-health-interventions. Acess on: 09 mai. 2024.

WU, Z.; MCGOOGAN, J. M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA, [s. l.], v. 323, n. 13, 2020. Avaliable from: https://jamanetwork.com/journals/jama/fullarticle/2762130#google_vignette. Acess on: 11 mai. 2024. DOI: https://doi.org/10.1001/jama.2020.2648

ZHANG, J. et al. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. Emerging Microbes & Infections, [s. l.], v. 10, n. 1, p. 1598–1608, 2021. Avaliable from: https://pubmed.ncbi.nlm.nih.gov/34278956/. Acess on: 10 mai. 2024. DOI: https://doi.org/10.1080/22221751.2021.1957401

Downloads

Published

2025-11-25

How to Cite

Rocha, G. S., Zanuzzi, T. R. L., Villela, E. F. de M., & Oliveira, F. M. (2025). EVALUATION OF THE EPIDEMIOLOGICAL IMPACT OF VACCINATION AGAINST SARS-COV-2 IN THE STATE OF GOIÁS IN 2021. Interdisciplinary Studies Journal, 7(6), 01–12. https://doi.org/10.56579/rei.v7i5.1791

Issue

Vol. 7 No. 6 (2025): JOURNAL OF INTERDISCIPLINARY STUDIES

Section

ARTICLES

License

Copyright (c) 2025 Interdisciplinary Studies Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The Journal of Interdisciplinary Studies adopts the Creative Commons Attribution 4.0 International License (CC BY 4.0), which allows for sharing and adapting the work, including for commercial purposes, provided proper attribution is given and the original publication in this journal is acknowledged.

Metrics